16 December 2015 - PaxVax Inc., a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases, today announced that the U.S. FDA has accepted for filing and review the BLA for its affiliate PaxVax Bermuda Ltd.’s single-dose oral cholera vaccine Vaxchora.

For more details, go to: http://www.paxvax.com/about/news/us-food-and-drug-administration-accepts-biologics-license-application-paxvax’s-single